Which common infections are treated with linezolid?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Linezolid: Common Clinical Indications

Linezolid is primarily prescribed for serious infections caused by resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multi-drug resistant Streptococcus pneumoniae. 1

FDA-Approved Indications

The drug label specifies the following approved uses 1:

  • Vancomycin-resistant Enterococcus faecium infections (VRE)
  • Hospital-acquired pneumonia caused by S. aureus (including MRSA)
  • Community-acquired pneumonia caused by S. pneumoniae (including multi-drug resistant strains)
  • Complicated skin and skin structure infections (cSSSI)
  • Uncomplicated skin and skin structure infections caused by methicillin-susceptible S. aureus or Streptococcus pyogenes

Guideline-Supported Uses

Skin and Soft Tissue Infections

Linezolid is recommended as an alternative to vancomycin for empiric coverage of MRSA in complicated skin and soft tissue infections, particularly in neutropenic or immunocompromised patients. 2 The 2014 IDSA guidelines position it alongside vancomycin, daptomycin, and ceftaroline for gram-positive coverage when MRSA is suspected.

Bacteremia Considerations

While linezolid has activity against MRSA bacteremia, it should NOT be used as first-line therapy for S. aureus bacteremia. 3 The 2023 IDSA guidance notes that linezolid lacks robust clinical trial data for this indication and did not meet noninferiority criteria in pooled analyses. Vancomycin or daptomycin remain preferred agents.

Critical Limitation: Catheter-Related Infections

Linezolid is explicitly contraindicated for catheter-related bloodstream infections due to an observed mortality imbalance in clinical trials (21.5% vs 16.0% with vancomycin). 1 This excess mortality occurred primarily in patients with Gram-negative or mixed infections, as linezolid has no activity against Gram-negative pathogens.

Clinical Advantages

Linezolid offers several practical benefits 1, 4:

  • 100% oral bioavailability - IV and oral doses are identical (600 mg every 12 hours)
  • Excellent tissue penetration for pneumonia and soft tissue infections
  • Bactericidal against most streptococci; bacteriostatic against staphylococci and enterococci

Key Safety Concerns

Myelosuppression

Complete blood counts must be monitored weekly, especially for treatment exceeding 2 weeks. 1 Thrombocytopenia, anemia, and leukopenia are dose- and duration-dependent. Discontinue if worsening myelosuppression develops.

Duration Limits

Avoid prolonged use beyond 28 days when possible. Peripheral and optic neuropathy emerge with extended therapy (3-6 months). 5

Drug Interactions

Linezolid is a reversible MAO inhibitor 1:

  • Avoid tyramine-rich foods (can cause hypertensive crisis)
  • Avoid pseudoephedrine/phenylpropanolamine (mean BP increase of 32-38 mmHg)
  • Monitor for serotonin syndrome with SSRIs or other serotonergic agents

Resistance Considerations

Resistance develops primarily in patients with unremoved prosthetic devices or undrained abscesses. 1 Point mutations in 23S rRNA confer resistance. To preserve activity, restrict linezolid use to infections with high morbidity/mortality caused by documented resistant organisms. 5

Practical Algorithm

Use linezolid when:

  1. Documented VRE infection (any site)
  2. MRSA pneumonia (hospital or community-acquired) where vancomycin is contraindicated or failing
  3. Complicated skin/soft tissue infections with MRSA when oral step-down therapy is needed
  4. Multi-drug resistant S. pneumoniae pneumonia

Do NOT use linezolid for:

  • Catheter-related bloodstream infections
  • S. aureus bacteremia (use vancomycin or daptomycin)
  • Any suspected Gram-negative infection
  • Empiric therapy without MRSA/VRE suspicion

References

4
Research

Linezolid: a review of its properties, function, and use in critical care.

Drug design, development and therapy, 2018

Related Questions

Which bacteria are covered by Zyvox (linezolid)?
Is the bioavailability of the oral tablet and intravenous formulation of linezolid the same?
Are there any drug-drug interactions between doxycycline and linezolid?
For a wound infection, how many days should linezolid 600 mg be administered orally every 12 hours?
What is the appropriate dosage of linezolid for treating MRSA infection in adults and children, including route, frequency, duration, and adjustments for renal or hepatic impairment?
When is testing for matrix metalloproteinase‑9 (MMP‑9) indicated, and how should elevated MMP‑9 levels be managed?
How should I manage a patient with flank pain, urinary tract infection since Monday, nausea and dizziness who is taking nitrofurantoin every 6 hours and phenazopyridine (Pyridium) every 8 hours?
In a 26-year-old female with acute renal failure (serum creatinine 14 mg/dL), severe anemia, hyperphosphatemia, secondary hyperparathyroidism, and a positive perinuclear anti-neutrophil cytoplasmic antibody (p‑ANCA) level of 133 AU/mL after normal creatinine five months ago, what is the appropriate next management?
Can adalimumab cause eosinophilia?
What is the likely diagnosis for cervical spine pain triggered by car bumps and rapid turns, and how should it be evaluated and managed?
What is the likely diagnosis and recommended management for a painless, firm, mobile lump behind the ear?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.